Literature DB >> 20861231

Androgen receptor-dependent and independent atheroprotection by testosterone in male mice.

Johan Bourghardt1, Anna S K Wilhelmson, Camilla Alexanderson, Karel De Gendt, Guido Verhoeven, Alexandra Krettek, Claes Ohlsson, Asa Tivesten.   

Abstract

The atheroprotective effect of testosterone is thought to require aromatization of testosterone to estradiol, but no study has adequately addressed the role of the androgen receptor (AR), the major pathway for the physiological effects of testosterone. We used AR knockout (ARKO) mice on apolipoprotein E-deficient background to study the role of the AR in testosterone atheroprotection in male mice. Because ARKO mice are testosterone deficient, we sham operated or orchiectomized (Orx) the mice before puberty, and Orx mice were supplemented with placebo or a physiological testosterone dose. From 8 to 16 wk of age, the mice consumed a high-fat diet. In the aortic root, ARKO mice showed increased atherosclerotic lesion area (+80%, P < 0.05). Compared with placebo, testosterone reduced lesion area both in Orx wild-type (WT) mice (by 50%, P < 0.001) and ARKO mice (by 24%, P < 0.05). However, lesion area was larger in testosterone-supplemented ARKO compared with testosterone-supplemented WT mice (+57%, P < 0.05). In WT mice, testosterone reduced the presence of a necrotic core in the plaque (80% among placebo-treated vs. 12% among testosterone-treated mice; P < 0.05), whereas there was no significant effect in ARKO mice (P = 0.20). In conclusion, ARKO mice on apolipoprotein E-deficient background display accelerated atherosclerosis. Testosterone treatment reduced atherosclerosis in both WT and ARKO mice. However, the effect on lesion area and complexity was more pronounced in WT than in ARKO mice, and lesion area was larger in ARKO mice even after testosterone supplementation. These results are consistent with an AR-dependent as well as an AR-independent component of testosterone atheroprotection in male mice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861231     DOI: 10.1210/en.2010-0663

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  36 in total

1.  New therapy via targeting androgen receptor in monocytes/macrophages to battle atherosclerosis.

Authors:  Chiung-Kuei Huang; Haiyan Pang; Lin Wang; Yuanjie Niu; Jie Luo; Eugene Chang; Janet D Sparks; Soo Ok Lee; Chawnshang Chang
Journal:  Hypertension       Date:  2014-03-31       Impact factor: 10.190

2.  Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains.

Authors:  O Moran; L J V Galietta; O Zegarra-Moran
Journal:  Cell Mol Life Sci       Date:  2005-02       Impact factor: 9.261

3.  Effect of resveratrol and orchidectomy on the vasorelaxing influence of perivascular adipose tissue.

Authors:  Charlotte Boydens; Bart Pauwels; Johan Van de Voorde
Journal:  Heart Vessels       Date:  2015-03-31       Impact factor: 2.037

Review 4.  Sex differences in vascular physiology and pathophysiology: estrogen and androgen signaling in health and disease.

Authors:  Austin C Boese; Seong C Kim; Ke-Jie Yin; Jean-Pyo Lee; Milton H Hamblin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

Review 5.  Anabolic androgenic steroids and intracellular calcium signaling: a mini review on mechanisms and physiological implications.

Authors:  J M Vicencio; M Estrada; D Galvis; R Bravo; A E Contreras; D Rotter; G Szabadkai; J A Hill; B A Rothermel; E Jaimovich; S Lavandero
Journal:  Mini Rev Med Chem       Date:  2011-05       Impact factor: 3.862

6.  Testosterone deficiency accelerates early stage atherosclerosis in miniature pigs fed a high-fat and high-cholesterol diet: urine 1H NMR metabolomics targeted analysis.

Authors:  Liqun Deng; Danting Fu; Liang Zhu; Junjie Huang; Yun Ling; Zhaowei Cai
Journal:  Mol Cell Biochem       Date:  2020-11-23       Impact factor: 3.396

Review 7.  [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].

Authors:  C Tschöpe; B Kherad; F Spillmann; C A Schneider; B Pieske; F Krackhardt
Journal:  Herz       Date:  2016-04-15       Impact factor: 1.443

8.  Androgen receptor promotes abdominal aortic aneurysm development via modulating inflammatory interleukin-1α and transforming growth factor-β1 expression.

Authors:  Chiung-Kuei Huang; Jie Luo; Kuo-Pao Lai; Ronghao Wang; Haiyan Pang; Eugene Chang; Chen Yan; Janet Sparks; Soo Ok Lee; Joshua Cho; Chawnshang Chang
Journal:  Hypertension       Date:  2015-10       Impact factor: 10.190

9.  Endogenous androgen deficiency enhances diet-induced hypercholesterolemia and atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Nicholas W Hatch; Sarah J Srodulski; Huei-Wei Chan; Xuan Zhang; Lisa R Tannock; Victoria L King
Journal:  Gend Med       Date:  2012-09-13

Review 10.  Basic Science Evidence for the Link Between Erectile Dysfunction and Cardiometabolic Dysfunction.

Authors:  Biljana Musicki; Anthony J Bella; Trinity J Bivalacqua; Kelvin P Davies; Michael E DiSanto; Nestor F Gonzalez-Cadavid; Johanna L Hannan; Noel N Kim; Carol A Podlasek; Christopher J Wingard; Arthur L Burnett
Journal:  J Sex Med       Date:  2015-12-08       Impact factor: 3.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.